NCT06802809View on ClinicalTrials.gov

Efficacy of Probiotic Lactobacillus Crispatus M247 in Promoting High-risk Human Papillomavirus (HR-HPV) Infection Clearance and Modifying Vaginal Microbiota

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 5, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

December 30, 2024

Conditions

Human Papillomavirus Infection

Interventions

DIETARY_SUPPLEMENT

Lactobacillus crispatus M247 (Crispact®)

Crispact® is a probiotic food supplement containing Lactobacillus crispatus M247.

OTHER

Placebo

The placebo does not contain the active probiotic strain and consists of inactive excipients.

Trial Locations (3)

90127

"Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone di Palermo", Palermo

95121

"Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco", Catania

96016

Nuovo Ospedale di Lentini, Lentini

All Listed Sponsors

collaborator

Università degli Studi dell'Insubria

OTHER

lead

Liaquat University of Medical & Health Sciences

OTHER

NCT06802809 - Efficacy of Probiotic Lactobacillus Crispatus M247 in Promoting High-risk Human Papillomavirus (HR-HPV) Infection Clearance and Modifying Vaginal Microbiota | Biotech Hunter | Biotech Hunter